<code id='2364998157'></code><style id='2364998157'></style>

<acronym id='2364998157'></acronym>

<center id='2364998157'><center id='2364998157'><tfoot id='2364998157'></tfoot></center><abbr id='2364998157'><dir id='2364998157'><tfoot id='2364998157'></tfoot><noframes id='2364998157'>

<optgroup id='2364998157'><strike id='2364998157'><sup id='2364998157'></sup></strike><code id='2364998157'></code></optgroup>

<b id='2364998157'><label id='2364998157'><select id='2364998157'><dt id='2364998157'><span id='2364998157'></span></dt></select></label></b><u id='2364998157'></u>

~~<i id='2364998157'><strike id='2364998157'><tt id='2364998157'><pre id='2364998157'></pre></tt></strike></i>~~

Home» leisure time» leisure time

leisure time

leisure time

author：focus 2025-09-29 12:48:46 Page View：54727

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

advertisement

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Charles Manson follower Leslie Van Houten released from prison after 53 years
Next article： Tori Bowie and the unacceptable rates of Black maternal death

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Elizabeth Holmes on track for early release from her 11

Elizabeth Holmes on track for early release from her 11

SANFRANCISCO--DisgracedTheranosCEOElizabethHolmeshasapparentlybehavedwellenoughduringthefirstsixweek

23andMe had bad news about my health. I wish a person had delivered it

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

CMS got Medicare Advantage quality rating wrong, judge rules

AdobeThefederalgovernmentinappropriatelyloweredthe2024MedicareAdvantagestarratingsofSCANHealthPlan,w

read more